LUMO Key Statistics, Chart & Performance
The current stock price of LUMO is 4.34 USD. In the past month the price decreased by -0.46%. In the past year, price increased by 52.28%.
LUMO Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to LUMO. When comparing the yearly performance of all stocks, LUMO is one of the better performing stocks in the market, outperforming 89.62% of all stocks.
LUMO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LUMO. While LUMO seems to be doing ok healthwise, there are quite some concerns on its profitability.
LUMO Financial Highlights
Over the last trailing twelve months LUMO reported a non-GAAP Earnings per Share(EPS) of -4.29. The EPS decreased by -6.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -199.97% | ||
| ROE | -710.54% | ||
| Debt/Equity | 0 |
LUMO Forecast & Estimates
10 analysts have analysed LUMO and the average price target is 9.88 USD. This implies a price increase of 127.68% is expected in the next year compared to the current price of 4.34.
For the next year, analysts expect an EPS growth of 8.71% and a revenue growth 385.58% for LUMO
LUMO Ownership
About LUMO
Company Profile
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. The company is headquartered in Austin, Texas and currently employs 30 full-time employees. The company went IPO on 2011-11-11. The firm is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders that require injectable recombinant human growth hormone (rhGH). LUM-201 is a tablet formulation that is intended to be administered once daily. LUM-201 stimulates GH via the GH secretagogue receptor (GHSR1a), also known as the ghrelin receptor, and also suppresses the release of somatostatin, thus providing a differentiated mechanism of action to treat some rare endocrine disorders (involving a deficiency of GH) by increasing the amplitude of endogenous, pulsatile GH secretion. Lumos Pharma Sub, Inc. (Private Lumos) is its subsidiary.
Company Info
LUMOS PHARMA INC
4200 Marathon Blvd., Suite 200
Austin TEXAS 78756 US
CEO: Richard J. Hawkins
Employees: 33
Phone: 15122152630
LUMOS PHARMA INC / LUMO FAQ
What does LUMO do?
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. The company is headquartered in Austin, Texas and currently employs 30 full-time employees. The company went IPO on 2011-11-11. The firm is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders that require injectable recombinant human growth hormone (rhGH). LUM-201 is a tablet formulation that is intended to be administered once daily. LUM-201 stimulates GH via the GH secretagogue receptor (GHSR1a), also known as the ghrelin receptor, and also suppresses the release of somatostatin, thus providing a differentiated mechanism of action to treat some rare endocrine disorders (involving a deficiency of GH) by increasing the amplitude of endogenous, pulsatile GH secretion. Lumos Pharma Sub, Inc. (Private Lumos) is its subsidiary.
What is the stock price of LUMOS PHARMA INC today?
The current stock price of LUMO is 4.34 USD.
Does LUMO stock pay dividends?
LUMO does not pay a dividend.
What is the ChartMill rating of LUMOS PHARMA INC stock?
LUMO has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for LUMO stock?
LUMOS PHARMA INC (LUMO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.29).